Imprese · 22/10/20261 min di lettura
Tikva Allocell Selected to Present Preclinical CD19.SB9.CAR-EBVST Data at ACR Convergence 2026
Traduzione automatica locale · Lingua originale della fonte
Riepilogo
Oral presentation will feature preclinical research evaluating Tikva's armored allogeneic CD19 CAR T-cell therapy as a potential lymphodepletion-free approach for systemic lupus erythematosus SINGAPORE, Oct. 22, 2026…